

# Journal of Clinical Biochemistry and Nutrition

The Official Journal of the Society for Free Radical Research Japan

## INSTRUCTION TO AUTHORS

### AIMS & SCOPE

Journal of Clinical Biochemistry and Nutrition (JCBN) is an international, interdisciplinary publication encompassing chemical, biochemical, physiological, pathological, toxicological and medical approaches to research on lipid peroxidation, free radicals, oxidative stress and nutrition. The Journal welcomes original contributions dealing with all aspects of clinical biochemistry and clinical nutrition including both *in vitro* and *in vivo* studies.

### PUBLICATIONS

*Original Articles:* Peer-reviewed, high-quality, concise research investigations that represent new and significant contributions to science.

*Review Articles:* Reviews of major areas or sub-areas in clinical biochemistry and clinical nutrition. These articles are peer-reviewed. Articles may be of any length.

*Serial Reviews:* A collection of normally invited reviews on a specific topic.

*Letters to the Editor:* Letters dealing with published articles or matters of interest to free radical researchers are invited. They should be short (not more than 400 words), typed double-spaced, and include references where appropriate. Where a published article is involved, the original author(s) will be invited to submit a response.

*Announcements and Calendar:* Providing notices of forthcoming meetings, courses, and other events relevant to clinical biochemistry and clinical nutrition researchers. All such items will be listed (free of charge) in the journal issues preceding the event and will be updated upon request.

### EDITORIAL REVIEW and ACCEPTANCE

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are single-blind peer reviewed by two anonymous reviewers, the Referee selected by Executive Editors, and the Editor. Final acceptance or rejection rests with the Editor-in-Chief, who reserves the right to refuse any material for publication. Authors may present names of potential reviewers and of reviewers whom they would prefer not to review the manuscript. The choice of reviewers remains the Editor's prerogative. A manuscript requiring revision will be returned to the author by email, along with specific suggestions for revision. Authors should follow the instructions below to submit revised manuscripts:

- The author should reply to the suggestions clearly in the

“Author's Response” section by indicating places where revisions have been made, and/or by stating reasons for disregarding other suggestions if they are thought to be unacceptable.

- Modified parts should be highlighted using underline or colored font.

Manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field. They should be written in a clear, concise, direct style. Where contributions are judged as acceptable for publication on the basis of scientific content, the Editor and the Publisher reserve the right to modify typescripts to eliminate ambiguity and repetition and to improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.

### DUPLICATE PUBLICATION and SCIENTIFIC FRAUD

In cases of suspected scientific misconduct (fabrication or falsification of data, double publication, or plagiarism), the journal will conduct a preliminary investigation. If scientific misconduct is found, the journal will contact the corresponding author's institution and funding agencies. JCBN will not consider publication of any papers by the offending authors for a period of 1 year or longer depending on the circumstances of each case.

### SUBMISSION OF MANUSCRIPTS

All articles submitted to the Journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. Manuscripts (Original Articles, Review Articles or Serial Reviews), with figures and tables, should be submitted electronically via our website, <http://www.editorialmanager.com/jcbtn/>. For assistance, please contact the Editorial Office of JCBN below:

Editorial Secretariat  
Journal of Clinical Biochemistry and Nutrition  
E-mail: [jcbtn@nacoss.com](mailto:jcbtn@nacoss.com)  
HP: <http://sfrj.umin.jp/JCBN.htm>

Letters to the Editors and items for the Announcements and Calendar section may be sent by e-mail to the Editorial Secretariat (address above).

All pages should be numbered consecutively in the top right-hand corner, beginning with the title page.

### COVERING LETTER

A covering letter should be attached and the following information should be included:

- **A declaration** that the paper is being submitted for consideration for publication in JCBN. The content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.
- **All authors' agreement:** acknowledgment that all authors have contributed significantly, and that all authors are in agreement with the content of the manuscript. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author's contribution to the paper is to be quantified.
- **Contact details** at which the corresponding author can be contacted, including mailing address, telephone and fax numbers, and an email address.
- **If tables or figures have been reproduced from another source,** a letter from the copyright holder (usually the Publisher), stating authorization to reproduce the material, must be attached to the covering letter.
- **The salient and novel findings** of the paper should be described in a concise paragraph.
- The names and addresses of at least **three potential reviewers** (including telephone and fax numbers and e-mail address). If there are compelling reasons for excluding particular individuals as potential reviewers, details can be mentioned. However, the ultimate reviewer selection is at the Editors' discretion.

### AUTHOR MATERIAL ARCHIVE POLICY

Authors who require the return of any submitted material that is accepted for publication should inform the Editorial Office after acceptance. If no indication is given that author material should be returned, Nakanishi Printing Co. Ltd. will dispose of all hardcopy and electronic material two months after publication.

### FINANCIAL DISCLOSURE

Authors should declare any financial support or relationship that may pose conflict of interest as Financial Disclosure. Financial Disclosure format can be obtained from our website. [Click here.](#)

### ETHICAL CONSIDERATIONS

Authors must state that the protocol for the research proj-

ect has been approved by a suitably constituted Ethics Committee of the institution and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All investigations on human subjects must include a statement that the subject gave informed consent. Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used).

Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national guidelines for animal usage in research.

Generally, diethyl ether should not be used for animal anesthesia. When diethyl ether is inevitably used for anesthesia, the authors must clearly explain the reason to use it in the manuscript.

### CLINICAL TRIALS

*JCBN* requires that all clinical trials submitted for its consideration are registered in a publicly accessible database. Authors should include the name of the trial register and their clinical trial registration number at the end of their summary. If you wish the editor(s) to consider an unregistered trial, please explain briefly why the trial has not been registered.

### COPYRIGHT

Upon acceptance of an article, authors will be asked to transfer copyright. This transfer will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript. A form facilitating transfer of copyright will be provided after acceptance.

### STYLE OF THE MANUSCRIPT

Manuscripts should follow the style of the Vancouver agreement detailed in the International Committee of Medical Journal Editors' revised 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication'.

*General rules:* The following instructions should be adhered to:

- Lines should be double-spaced
- Do not use the carriage return (Enter) at the end of lines within a paragraph.
- Turn the hyphenation option off; include only those hyphens that are essential to the meaning.
- Specify any special characters used to represent non-keyboard characters.
- Take care not to use l (ell) for 1 (one), O (capital o) for 0 (zero) or ß (German esszett) for β (Greek beta).
- Use a tab, not spaces, to separate data points in tables. If

you use a table editor function, ensure that each data point is contained within a unique cell (i.e. do not use carriage returns within cells).

*Spelling:* The Journal uses US spelling and authors should therefore follow the latest edition of the Merriam-Webster's Collegiate Dictionary.

*Units:* All measurements must be given in SI or SI-derived units. Please go to the Bureau International des Poids et Mesures (BIPM) website for more information about SI units. Temperatures denoted by an unqualified degree symbol are assumed to be Celsius. For solution strengths, percentages should be expressed by the sign %, followed in cases of ambiguity by w/w, w/v, or v/v [e.g., 5% (w/v) means 5 g/100 ml].

*Abbreviations and Nomenclature:* Stylistic details must be kept constant. For example, P450 is not typed P450; electron spin resonance is abbreviated either ESR or EPR (for electron paramagnetic resonance). Either can be used, but both should be given and stated as equivalent at the first mention. (This is the recommendation of the International EPR Society.) Formulae for radicals follow IUPAC recommendations and contain a superscripted (not centered) dot that precedes a charge, if any. Thus, superoxide is represented by  $O_2^{\cdot-}$ , not  $O_2^-$ ,  $O_2^{\cdot}$ , or some other permutation.

Other examples are: HO $\cdot$  or  $\cdot$ OH (not OH $\cdot$ ), RO $\cdot$ , ROO $\cdot$ / $\cdot$ NO $_2$ ,  $\cdot$ CH $_2$ OH, etc. In the text, names of radicals are preferred, rather than using formulas in the middle of sentences. For names of radicals, use alkoxy, peroxy, and hydroxyl and not alkoxy, peroxy, etc. (correct nomenclature requires the 'l' on the end of radicals, as in methyl, hydroxyl, etc.). Use *tert.*, not t-, etc., for abbreviations.

For example, CORRECT: tert-butoxyl, *sec*-peroxyl; INCORRECT: t-butoxy, s-peroxy.

Where possible, nomenclature and abbreviations should be in accordance with internationally agreed rules. When an enzyme or compound is first mentioned in the text, specification by its code number accompanied by its systematic name (as distinct from its trivial name) is requested by the Editors, but not checked for correctness.

Official names of drugs are preferred to trade names.

Standard three-letter codes for the common amino acids may be used freely and without definition, but the one-letter codes should be restricted to comparisons of long protein sequences. Similar considerations apply to nucleosides and nucleotides. Standard three-letter codes for carbohydrates and for purine and pyrimidine bases may also be used. All other abbreviations should be defined when they first appear in the text. If an extensive list of abbreviations is used, please provide an alphabetical list with definitions followed by the references at the end of the article.

*Genetic nomenclature:* Standard genetic nomenclature should be used. For further information, including relevant

websites, authors should refer to the genetic nomenclature guide in Trends in Genetics (Elsevier Science, 1998). Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL and GenBank on a daily basis. The suggested wording for referring to accession-number information is: 'These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345'. Links are as follows: DNA Data Bank of Japan (DDBJ) EMBL Nucleotide Sequence Submissions GenBank

## PARTS OF THE MANUSCRIPT

Responsibility for the accuracy of the material in the manuscript, including bibliographic citations, lies entirely with the authors.

Manuscripts parts should be presented in the following order: (i) title page, (ii) summary, abbreviations, and clinical trial register and their clinical registration number at the end of summary, (iii) text (including Introduction, Material and Methods, Results, Discussion), (iv) acknowledgments (if any), (v) references, (vi) appendices (if any), (vii) figure legends, (viii) tables (each table complete with title and footnotes) and (ix) figures. Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

***File Format:* All manuscript, including main text, tables, figures and figure legends, should be submitted in one pdf file.**

Please note that we cannot accept Word files, and PowerPoint files. These files must be converted to pdf file type. Converting PowerPoint files frequently results in unexpected changes to the figures (e.g. missing or shifted text; shifted image elements). We recommend you not to create figures by PowerPoint. If you do try to convert from PowerPoint to pdf file type, be very careful to compare the final version to your original.

*Title page:* The title page should contain: (i) the title of the paper, (ii) the full names of the authors, (iii) the addresses of the institutions at which the work was carried out, (iv) the full postal and email address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript should be sent. The present address of any author, if different from that where the work was carried out, should be supplied in a footnote, (v) the precise word count of the manuscript (excluding references for Original Articles; including references for Review Articles, and Letters to the Editor), (vi) number of tables/figures. The title should be short (preferably less than 120 letters), informative and contain the major key words. Do not use

unnecessary words such as ‘Study of’ or ‘Results on’, or abbreviations in the title. This page also should provide a short descriptive statement detailing the contributions of each co-author (e.g., study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis; obtained funding; administrative, technical, or material support; study supervision).

**Summary:** All articles must have a summary in bold style that states in 200 words or fewer the purpose, basic procedures, main findings and principal conclusions of the study. Data such as the number of test subjects and controls, strains of animals or viruses, drug dosages and routes of administration, tumor yields and latent periods, length of observation period, and magnitude of activity should be included. The summary should not contain abbreviations or references.

**Keywords:** Authors are requested to select about 5 keywords (each character of the keywords should be in bold style and should not be capitalized) in new line immediately below the summary for indexing. These keywords should cover precisely the contents of the submitted paper and should give readers sufficient information as to the relevance of the paper to their particular field.

**Text:** Authors should use the following subheadings to divide the sections of their manuscript: Introduction, Materials and Methods, Results, and Discussion.

**Introduction:** The introduction should mention the purpose of the investigation, its relation to other work in the field, and the reasons for undertaking the research. Brief reference to the most relevant papers is sufficient.

**Materials and Methods:** Description of methods should be brief, but with sufficient detail to enable others to reproduce the experiments. When published procedures are used, the appropriate references should be cited. Only new and significant modifications of previously published procedures require complete description. Names of products and manufacturers with their locations (city and state/country) should be given and sources of animals and tumors should always be indicated. Duncan’s multiple range test should not be used for post-hoc data analysis. Fisher’s LDS can not be employed for the test for more than 4 groups.

**Results:** The results should be described concisely. Tables and figures should be used only if they are indispensable for the comprehension of data.

**Discussion:** The results should be interpreted and related to

existing knowledge in the field. Information already given in the introduction or results should not be repeated.

**Acknowledgments:** The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors’ industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Personal thanks and thanks to anonymous reviewers are not appropriate.

**Conflict of Interest:** All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work.

**References:** The Vancouver system of referencing should be used (examples are given below). In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited in tables or figure legends, number according to the first identification of the table or figure in the text. In the reference list, cite the names of all authors when there are six or fewer; when seven or more, list the first three followed by et al. Do not use *ibid.* or *op cit.* Reference to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g. Smith A, 2000, unpublished data). All citations mentioned in the text, tables or figures must be listed in the reference list. When a reference is accepted but still in press, authors must submit it to reviewers if requested. If authors refuse to submit, the manuscript might be rejected because reviewers cannot review the context of the articles in press. Names of journals should be abbreviated in the style used in *Index Medicus*. Authors are responsible for the accuracy of the references.

Examples of reference style are as follows

Journal article:

- 1 Takagi T, Naito Y, Yoshikawa T. The expression of heme oxygenase-1 induced by lansoprazole. *J Clin Biochem Nutr* 2009; **45**: 9–13

Journal articles published ahead of issue (print or online):

An online article that has not yet been published in an issue (therefore has no volume, issue or page numbers) can be cited by its Digital Object Identifier (DOI). The DOI will remain valid and allow an article to be tracked even after its allocation to an issue.

- 2 Omatsu T, Naito Y, Handa O, *et al.* Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell

injury. *J Gastroenterol* 2010. DOI: 10.1007/s00535-010-0213-9

Book:

- 3 Papas AM. *The vitamin E factor: the miraculous antioxidant for the prevention and treatment of heart disease, cancer, and aging*. New York: Harper Collins Publishers, Inc., 1999; 123–125.

Chapter in a Book:

- 4 Kokura S and Aw TY. Anoxia/reoxygenation induced inflammatory response: Role of cellular thiol redox status in NF- $\kappa$ B activation and endothelial cell adhesion molecule expression. In: Yoshikawa T, Toyokuni S, Yamamoto Y, and Naito Y, eds. *Free Radicals in Chemistry, Biology and Medicine*, London: OICA International (UK) Limited, 2000; 495–500.

Published on the World Wide Web:

Online journal can be cited only when they have DOI number.

- 5 Schriger DL, Ouk S, Altman DG. The use of the World Wide Web by medical journals in 2003 and 2005: an observational study. *Pediatrics*. 2007 Jan; **119**(1): e53–e60. DOI: 10.1542/peds.2006-1538

Online document:

- 6 WHO helps Nigeria control cholera in Borno state. World Health Organization. <http://www.afro.who.int/news/who-helps-nigeria-control-cholera-borno-state>. Accessed 12 Jan 2018.

*Appendices:* These should be placed at the end of the paper, numbered in Roman numerals and referred to in the text. If written by a person other than the author of the main text, the writer's name should be included below the title.

*Figure legends:* Type figure legends on a separate sheet. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

*Tables:* Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate sheet with the legend above. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be

used (in that order) and \*, \*\*, \*\*\* should be reserved for *p* values. Statistical measures such as SD or SEM should be identified in the headings. Tables should be submitted in Microsoft word or excel. Image files and groupings of text boxes should be avoided.

*Figures:* All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Figures should be used to illustrate experimental results clearly. Illustrations for reproduction should normally be about twice the final size required as figures are often reduced to a one-column width. Symbols, lettering and lines should be sufficiently large and clear to be legible after reduction. Photographs of tissues, cells, or subcellular components should be included only when they are essential. Figures should be supplied as separate files, with the figure number incorporated in the file name. Text presented in tables and figures should be 8–12 point Verdana and Symbol. Panel labels of Figures must be 16 point Verdana bold letters (A, B, C). Please avoid placing panel labels over images. For image quality specifications, please refer the end of Instruction to Authors.\*

## PROOFS

It is essential that corresponding authors supply an email address to which proofs can be emailed. Authors of Original Contributions and Review Articles will receive proofs. Because acceptance is based upon the submitted version of the paper, it is essential that no new material be inserted in the text at the time of proofreading; furthermore, no alteration to style or meaning will be permitted at this stage. Any new material that the authors wish to introduce for reasons of scientific accuracy will be checked by the Editors and a charge may be made for corrections. Authors are encouraged to return their proof corrections by e-mail. Authors will be given within 2 working days (48 hours) turn-around time to return proof corrections. Any new material that the authors wish to introduce for reasons of scientific accuracy will be checked by the Editors and a charge may be made for corrections. Authors who will not be available to check their proofs should appoint someone to proofread their article. If the proof is not returned by the appointed date, it may be signed off on by the Editor or held over to the next issue.

## OFFPRINTS

A minimum of 100 offprints will be provided upon request, at the author's expense. If you have queries about offprints please email: [jcbn@nacoss.com](mailto:jcbn@nacoss.com).

## PUBLICATION

For information concerning your accepted manuscript, proofs, etc., please contact the Issue Manager at Nakanishi

Printing Co. Ltd. (Contact details provided on letter of acknowledgment sent to author after receipt of the manuscript by the Publisher.) Always quote JCBN and the article's Production Number.

**PUBLICATION FEES and COLOR FIGURE CHARGE**

Color figures may be included in your article, but generally this expense must be borne by the authors for print publication. Color figures are not charged for online publication. For color reproduction in print, you will receive information regarding the costs from the Editorial Secretariat after receipt of your accepted article. Please note: Because of technical complications that can arise in converting color figures to “gray scale” (for the printed version should you not opt for color in print), please submit in addition usable black-and-white files corresponding to all color illustrations. As only one figure caption may be used for both color and black and white versions of figures, please ensure that figure captions are meaningful for both versions, if applicable.

Since JCBN depends, in part, on the payment of page charges for its publication, payment of JPY10,000 or \$100 per printed page along with JPY70,000 or \$700 per online article are mandatory.

**CORRECTION CHARGE FOR ERRORS IN FIGURES**

Authors should carefully prepare the manuscripts. Failure to do so especially in figures will result in the extensive correction by the Publisher. As a correction charge for errors in figures, JPY2,000 or \$20 per figure will be added.

**\*IMAGE QUALITY SPECIFICATIONS**

All Images Must be Submitted At or Above Intended Display Size

Image Type	Description	Format	Color Mode	Resolution
Line Art	An image composed of lines and text, which does not contain tonal or shaded areas	ai, ppt(x), xls(x), pdf	Monochrome 1-bit or RGB	—
Halftone	A continuous tone photograph, which contains no text	tif, jpg, psd	RGB or Grayscale	300–350 dpi
Combination	Image contains halftone + text or line art elements	ai, ppt(x), xls(x), pdf	RGB or Grayscale	—

**SUPPLEMENTAL DATA CHARGE**

It will be possible to add the supplemental data (figures and tables) that enhances the quality of the article; the extra charge (JPY2,000 or \$20 per figure) will be added.

**ACCEPTED ARTICLES PUBLISHED ONLINE AHEAD OF PRINT**

Articles in this journal which have been peer-reviewed and accepted, but not yet copy-edited, are published in Advance Publication online through our website. Please refer to our web site indicated below.

[http://www.jstage.jst.go.jp/browse/jcbrn/advpub/0/\\_contents](http://www.jstage.jst.go.jp/browse/jcbrn/advpub/0/_contents)

Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. Advance Publication articles are complete and final, and represent official publication of the article and may be cited thus in patent applications, etc. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Advance Publication articles means that they do not yet have volume, issue or page numbers, so Advance Publication articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article (more information about DOIs).

as of March 30, 2016  
as of July 1, 2017  
as of March 1, 2018  
as of May 1, 2018  
as of May 17, 2018

## Financial Disclosure

Check the appropriate box and sign where indicated. All Authors must sign one of the statements below.

I, the undersigned Author, certify that I have **no financial arrangements** (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements, research support, major honoraria, etc.) with a company whose product figures prominently in the submitted manuscript or with a company making a competing product except as disclosed on a separate attachment. All funding sources supporting the work are acknowledged on the title page.

_____	_____
_____	_____
_____	_____
_____	_____

I, the undersigned Author, certify that I have **included on the title page of the manuscript any financial arrangements** (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements, research support, major honoraria, etc.) that I have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product. All funding sources supporting the work are acknowledged on the title page.

_____	_____
_____	_____
_____	_____
_____	_____